28th week of 2013 patent applcation highlights part 42 |
Patent application number | Title | Published |
20130178417 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF - The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. | 2013-07-11 |
20130178418 | NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization. | 2013-07-11 |
20130178419 | METHOD OF TREATING PAIN BY ADMINISTRATION OF NERVE GROWTH FACTOR - The invention provides methods and compositions for treatment of acute and chronic pain comprising the administration of Nerve Growth Factor. | 2013-07-11 |
20130178420 | NOVEL GLP-1 RECEPTOR MODULATORS - The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ | 2013-07-11 |
20130178421 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 2013-07-11 |
20130178422 | SPARC AND METHODS OF USE THEREOF - The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor. | 2013-07-11 |
20130178423 | SPARC AND METHODS OF USE THEREOF - The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor. | 2013-07-11 |
20130178424 | THERAPY FOR COMPLICATIONS OF DIABETES - A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET | 2013-07-11 |
20130178425 | METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST - Methods, systems, and compositions related to generating and using a solution rich in interleukin-1 receptor antagonist are provided. Methods include contacting a liquid comprising white blood cells with a solid extraction material and stimulating with an electromagnetic field to activate production of interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist can be separated from the solid extraction material. Methods for treating a site of inflammation in a patient include administering the solution rich in interleukin-1 receptor antagonist to the site of inflammation. | 2013-07-11 |
20130178426 | THERAPEUTIC AGENT FOR PULMONARY EMPHYSEMA - The invention has as its object the provision of a medicine capable of reducing a volume of emphysema-suffering pulmonary alveoli or alveolar sacs by means of a respiratory region volume inhibitor containing a coating film formation as a main component and capable of forming a coating film in a respiratory region, characterized by being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g/application, preferably 0.07 to 20 g/application and more preferably 0.5 to 5 g/application on each occasion. | 2013-07-11 |
20130178428 | LONG NONCODING RNA (LNCRNA) AS A BIOMARKER AND THERAPEUTIC MARKER IN CANCER - Long noncoding RNAs (lncRNAs) that may be used as cancer biomarkers and methods of diagnosing, prognosing and monitoring cancer including, but not limited to, cutaneous melanoma using said lncRNAs are provided herein. In some embodiments, the methods include steps of isolating one or more lncRNA transcripts in a biological sample from the subject; measuring a test level of the one or more isolated lncRNA transcripts; comparing the test level to a control level of the one or more lncRNA transcripts; and diagnosing or making a prognosis based on the lncRNA level. In some embodiments, the lncRNA transcript is an linc00340 transcript or variant thereof. These lncRNA transcripts may also be used as a therapeutic target in the treatment of cancer. | 2013-07-11 |
20130178429 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF - The present invention provides macrocyclic compounds of Formula (I): pharmaceutically acceptable salts thereof; and pharmaceutical compositions thereof, wherein R | 2013-07-11 |
20130178430 | Compositions for Prevention or Treatment of Hepatitis C Virus Containing ginsenoside Rg3 as an Active Ingredient - This invention is for the compound containing ginsenoside Rg3 as an active ingredient to prevent and treat Hepatitis C virus infection. Specifically, the ginsenoside Rg3 of this invention demonstrated the predominant antiviral activities and apotosis actions in a dose-dependent manner in the Hepatitis C virus infected cells (Huh 7.5.1). Confirmed that it reduces the levels of TNF-α and thioredoxin significantly, and increases phospho-NFκB. It also demonstrated same effectiveness as PegInterferone alpha-2b(PegIFN a-2b, Hepatitis C therapeutics), and has no cytotoxicity to human bodies. Thus, it may be used safely as an active ingredient of medical/pharmaceutical and health food compounds for preventing or treating Hepatitis C. | 2013-07-11 |
20130178431 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same. | 2013-07-11 |
20130178432 | COMPOSITIONS FOR CONTROLLING HEARTWORM INFESTATION - The present invention relates to ivermectin formulations for administration to pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse of conventional formulations. Preferred formulations are collars, collar strips, or medallions, attachments for collars, ear tags, bands which are affixed to limbs or parts of the body, adhesive strips and films, and peel-off films, or spot-on or pour-on forms which are administered at least twice a year up to around once a year. | 2013-07-11 |
20130178433 | METHOD OF TREATING HEMORRHOIDS USING MACROCYCLIC LACTONE COMPOUND - A method of treating hemorrhoids is disclosed. The method includes locally administering a composition including an effective amount of one or more macrocyclic lactone compounds, including avermectin compounds, milbemycin compounds, or mixture thereof and a pharmaceutically acceptable carrier to the affected anorectal region of an individual suffering from hemorrhoid. | 2013-07-11 |
20130178434 | METHOD OF TREATING OTITIS EXTERNA USING MACROCYCLIC LACTONE COMPOUND - A method of treating otitis externa is disclosed. The method includes topically applying an otic composition containing an effective amount of one or more macrocyclic lactone compounds, including avermectin compounds or milbemycin compounds and a pharmaceutically acceptable carrier into the external auditory canal and the auricle of an affected ear of an individual suffering from otitis externa. | 2013-07-11 |
20130178435 | Diagnostic Methods for Hematological Disorders - Provided are methods for prognosing a clinical outcome in a subject with a hematological disorder comprising determining a 3D telomeres organization signature of a test sample cell from the subject, wherein the 3D telomeres organization signature of the test sample cell is indicative of the clinical outcome of the subject. | 2013-07-11 |
20130178436 | COMPOSITION FOR PREVENTING, IMPROVING, OR TREATING RENAL DISEASE INCLUDING MAILLARD BROWNING REACTION PRODUCTS OF PANAX SPECIES PLANT EXTRACT - A composition for preventing, improving, or treating renal diseases, the composition including as an active ingredient a Maillard browning reaction product obtained by reacting ginsenoside Re, an extract of | 2013-07-11 |
20130178437 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION - The present invention relates to hydroxyalkyl starch (HAS) conjugates and to a method for preparing the hydroxyalkyl starch (HAS) conjugates, the hydroxyalkyl starch (HAS) conjugates comprising a hydroxyalkyl starch derivative and a cytotoxic agent, said conjugate having a structure according the following formula HAS′(-M) | 2013-07-11 |
20130178438 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 2013-07-11 |
20130178439 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE - The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier. | 2013-07-11 |
20130178440 | COMPOSITIONS AND METHODS FOR TREATING SKIN CANCER ASSOCIATED DISEASES - The invention provides compositions and methods for treating skin cancer associated diseases. Specifically, the invention relates to topically administering a signaling pathway inhibitor or a related compound to treat pre-cancerous skin lesions, skin tumors, and their associated diseases or disorders. | 2013-07-11 |
20130178441 | Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin - The present invention includes a method to reverse the trend towards progressive resistance to consecutive treatments for T-cell lymphoma in a patient. This method includes selecting a patient having T-cell lymphoma, wherein the patient has had at least one prior treatment for T-cell lymphoma, wherein the prior treatment comprises non-10-propargyl-10-deazaaminopterin; and administering to the patient a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaminopterin, whereby the trend towards progressive resistance is reversed. | 2013-07-11 |
20130178442 | GENE EXPRESSION PROFILES AND PRODUCTS FOR THE DIAGNOSIS AND PROGNOSIS OF POSTINJURY SYNOVITIS AND OSTEOARTHRITIS - Associations between inflammation and pain/function scores were tested by univariate and multivariate analyses. Gene expression was analyzed by microarray and real-time PCR comparing patients with and without synovial inflammation. Synovitis was present in 43% of patients presenting for arthroscopic menisectomy. Inflammation was associated with pre-operative Lysholm scores, independent of age, gender, and BMI. Synovial RNA microarray analysis revealed 260 genes differently expressed ≧2-fold between patients with and without synovitis. A chemokine signature identified in the “inflammatory” biopsies was confirmed by real-time PCR. In conclusion, in patients presenting for arthroscopic menisectomy, synovitis is associated with symptoms. Comparison of expression patterns revealed enrichment of chemokines associated with cellular recruitment and activation in patients with synovitis. These chemokines may represent targets for therapeutic intervention to reduce inflammatory symptoms in patients with meniscal injury. | 2013-07-11 |
20130178443 | PHENYLQUINAZOLINE DERIVATIVES - Novel quinazolinamide derivatives of the formula (I), in which R1-R43 and X have the meanings indicated in claim | 2013-07-11 |
20130178444 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes prodrugs of the compound of formula (I): | 2013-07-11 |
20130178445 | Novel Benzopyran Compounds, Compositions and Uses Thereof - Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans. | 2013-07-11 |
20130178446 | METHOD FOR DECREASING SEBUM PRODUCTION - The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin. | 2013-07-11 |
20130178447 | PESTICIDE COMPOSITION COMPRISING FOSETYL-ALUMINIUM, PROPAMOCARB-HCL AND AN INSECTICIDE ACTIVE SUBSTANCE - The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on fosetyl-Al, propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance. | 2013-07-11 |
20130178448 | Treatment of Respiratory Disorders - This invention relates to the treatment of respiratory disorders, and in particular respiratory disorders and oedema caused by pathogenic infections. In particular, the invention relates to orally administrable pharmaceutical compositions for treating respiratory disorders, and to methods of such treatment. The invention is particularly concerned with the treatment of respiratory disorders that are caused by viral infections, such as with influenza viral strains. The invention also extends to analgesic compositions and methods for treating inflammatory pain manifesting in a variety of diseases, and not only respiratory diseases. | 2013-07-11 |
20130178449 | 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs - This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydroxyvitamin D | 2013-07-11 |
20130178450 | METHODS FOR INCREASING THE PRODUCTION OR ACTIVITY OF CATALASE - Methods and compositions for increasing the production or activity of catalase in an animal are disclosed. The methods comprise administering vitamin D to the animal in an amount effective to increase catalase production or activity. Methods for treating catalase deficiency, extending the prime years of an animal's life, promoting health and wellness of an animal, and improving the quality of life for an animal through the vitamin D-mediated increase in catalase production or activity are also disclosed. Methods of screening for vitamin D mimetics based on their ability to increase the production or activity of catalase in cells in a manner similar to vitamin D are also disclosed. | 2013-07-11 |
20130178451 | METHOD OF TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM - The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D | 2013-07-11 |
20130178452 | PHARMACEUTICAL COMPOSITION CONTAINING A TETRAHYDROFOLIC ACID - The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition. | 2013-07-11 |
20130178453 | Cannabinoid Agonists - The present disclosure relates to compounds useful as agonists of the cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders, either alone or in combination therapy. The compounds of the invention have Formula (I). | 2013-07-11 |
20130178454 | COMBINATION OF TESTOSTERONE AND ORNITHINE DECARBOXYLASE (ODC) INHIBITORS - The present invention is generally directed to a method of increasing testosterone levels in a subject comprising; administration of testosterone or analogue thereof along with an ornithine decarboxylase (ODC) inhibitor. The method selectively promotes beneficial effects of testosterone, while preventing side effects associated with testosterone administration. The present invention also directed to pharmaceutical composition and kits comprising testosterone or analogue thereof; ornithine decarboxylase inhibitors. The composition selectively promotes beneficial effects of testosterone, while preventing side effects of testosterone administration. In some embodiments, the present invention relates to a method of treatment of low testosterone levels in a subject by administrating testosterone and ODC inhibitor while preventing side effects associated with testosterone administration. The method and composition of the invention particularly prevents potential adverse effects on the prostate in men and virilization in women. | 2013-07-11 |
20130178455 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. | 2013-07-11 |
20130178456 | ARYLETHYNYL DERIVATIVES - The present invention relates to ethynyl compounds of formula I | 2013-07-11 |
20130178457 | CANNABINOID RECEPTOR MODULATORS - Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I). | 2013-07-11 |
20130178458 | SUBSTITUTED (1-(METHYLSULFONYL)AZETIDIN-3-YL)(HETEROCYCLOALKYL)METHANONE ANALOGS AS ANTAGONISTS OF MUSCARINIC ACETYLCHOLINE M1 RECEPTORS - In one aspect, the invention relates to substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs, derivatives thereof, and related compounds, which are useful as antagonists of the muscarinic acetylcholine receptor M | 2013-07-11 |
20130178459 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME - Tricyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer. | 2013-07-11 |
20130178460 | THIENOPYRIMIDINE COMPOUNDS - The present invention relates to the use of novel compounds of Formula I: | 2013-07-11 |
20130178461 | INHIBITORS OF BRUTON'S TYROSINE KINASE - This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: | 2013-07-11 |
20130178462 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION - The present disclosure provides a series of compounds of the formula (I) | 2013-07-11 |
20130178463 | ENHANCED TRANSBUCCAL DRUG DELIVERY SYSTEM AND COMPOSITIONS - A buccal delivery system is disclosed suitable for delivery of a therapeutic agent to the oral cavity of a patient. The delivery system comprises a matrix for containing and releasing the therapeutic agent into the oral cavity and an alkyl N,N-disubstituted amino acetate in said matrix. A particularly preferred delivery system comprises a matrix containing an effective amount of therapeutic agent together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate salt. | 2013-07-11 |
20130178464 | DELTA CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, A PROCESS FOR ITS PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - Delta crystalline form of the compound of formula (I): | 2013-07-11 |
20130178465 | INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF - The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof. | 2013-07-11 |
20130178466 | Treatment of Microbial Infections - The invention provides compositions, medicaments and methods of treating microbial infections, and especially respiratory disorders caused by microbial infections. In particular, the invention relates to the treatment of respiratory diseases caused by pathogenic infections using certain either alkyl substituted or un-substituted 2-aryl acetic acid, or 2-aryl, N-hydroxyacetamide derivatives, or pentoxifylline, and to the use of these compounds in methods of treatment. | 2013-07-11 |
20130178467 | HIGHLY CONCENTRATED STABLE MELOXICAM SOLUTIONS - Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The formulation according to the invention has a shelf-life of up to 24 months or more. | 2013-07-11 |
20130178468 | HIV INTEGRASE INHIBITORS - Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: | 2013-07-11 |
20130178469 | NOVEL ANTIVIRAL AGENTS - The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided | 2013-07-11 |
20130178470 | HETEROCYCLIC AMINOBERBAMINE DERIVATIVES, THE PREPARATION PROCESS AND USE THEREOF - The present invention relates to a novel berbamine derivative of formula I or a pharmaceutically acceptable salt thereof, a process for preparation of the same, a pharmaceutical composition comprising said compound and its use in manufacture of an antitumor medicament. | 2013-07-11 |
20130178471 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2013-07-11 |
20130178472 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF - The invention relates to pyridine-pyridinone derivatives general formula (I): | 2013-07-11 |
20130178473 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR - Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof. | 2013-07-11 |
20130178474 | WATER TREATMENT COMPOSITION CONTAINING HALOGEN-RELEASING COMPOUND AND FLUOROPOLYMER - The present invention is directed to a water treatment composition, containing 50-99.9 wt. % of particulate halogen-releasing compound; and 0.1-10 wt. % of granular fluoropolymer, wherein all weight percentages are based on the total weight of the composition. The present invention is also directed to a water treatment composition, containing 50-99 wt. % of particulate halogen-releasing compound; 1-10 wt. % of aluminum sulfate; 0.5-15 wt. % of a sulfate salt selected from the group consisting of copper sulfate, zinc sulfate, and combinations thereof; and 0.1-10 wt. % of particulate polytetrafluoroethylene polymer, wherein all weight percentages are based on the total weight of the composition. One particular halogen-releasing compound is trichloroisocyanuric acid. | 2013-07-11 |
20130178475 | sGC STIMULATORS - Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. | 2013-07-11 |
20130178476 | METHOTREXATE COMPOSITION - A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution. | 2013-07-11 |
20130178477 | METHODS OF TREATING DIABETIC NEUROPATHY USING BENZENESULFONAMIDES - This invention is directed to methods of treating diabetic neuropathy, particularly, diabetic peripheral neuropathy, in a patient in need of treatment thereof. | 2013-07-11 |
20130178478 | PYRIDAZINE AMIDE COMPOUNDS - The present invention relates to the use of novel triazolopyridine derivatives of formula I: | 2013-07-11 |
20130178479 | PHARMACEUTICAL COMBINATIONS - The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol-3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases; and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 2013-07-11 |
20130178480 | Inhibitors of Advanced Glycation End Products - The present invention provides compounds of the formula, | 2013-07-11 |
20130178481 | HEXAHYDRO-1H-4,7-METHANOISOINDOLE-1,3-DIONE COMPOUNDS - The present invention is directed to therapeutic agents which are atypical antipsychotics and which are useful in the treatment of neurological and psychiatric disorders associated with dopamine D2 and serotonin 5-HT2A neurotransmission dysfunction. | 2013-07-11 |
20130178482 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMIN- O)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE - The present invention relates to the compound of the formula: | 2013-07-11 |
20130178483 | Methods and Compositions for Inhibition of Bone Resorption - Disclosed herein are methods and compounds for inhibiting bone and/or cartilage resorption in an individual. The methods comprise administering to the individual a composition comprising a therapeutically effective amount of a compound that is an irreversible inhibitor of a Bruton's tyrosine kinase (BTK), or a pharmaceutically acceptable salt thereof. Also described are irreversible inhibitors of Btk and methods for the preparation of the compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the inhibition of cancer metastasis, and for inhibition of bone or cartilage resorption in cancer patients. | 2013-07-11 |
20130178484 | TREATMENT OF GOUT AND HYPERURICEMIA - Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described. | 2013-07-11 |
20130178485 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES - The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines. | 2013-07-11 |
20130178486 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein A, R | 2013-07-11 |
20130178487 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES - The present invention relates to the use of quinazolines of formula (I), | 2013-07-11 |
20130178488 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES - The present invention relates to novel compounds that inhibit Lp-PLA | 2013-07-11 |
20130178489 | METHOD FOR FUNGICIDAL AND/OR BACTERICIDAL TREATMENT OF RESISTANT STRAINS USING ESSENTIAL OIL(S) - The present invention relates to a method for fungicidal and/or bactericidal treatment of plants or foodstuffs using one or more essential oil(s) that enable the treatment of strains resistant to synthetic fungicides and/or bactericides. | 2013-07-11 |
20130178490 | PEST CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PEST - The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more carbamate compound(s) selected from Group (A) shows an excellent controlling activity on a pest. Group (A): a group consisting of alanycarb, aldicarb, aldoxycarb, bendiocarb, benfuracarb, carbaryl, carbofuran, carbosulfan, cloethocarb, ethiofencarb, fenobucarb, fenothiocarb, fenoxycarb, furathiocarb, isoprocarb, metolcarb, methomyl, methiocarb, oxamyl, pirimicarb, pro poxur, XMC, thiodicarb and xylylcarb | 2013-07-11 |
20130178491 | FUNGICIDAL COMPOSITION - A composition comprising (i) a compound of formula (I) | 2013-07-11 |
20130178492 | PHARMACEUTICAL COMPOSITIONS COMPRISING HYDROMORPHONE AND NALOXONE - The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings. | 2013-07-11 |
20130178493 | USE OF 14,15-DIHYDRO-20,21-DINOREBURNAMENIN-14-OL FOR THE TREATMENT AND/OR PREVENTION OF SERIOUS DEPRESSION AND SLEEP/WAKING CYCLE DISORDERS - The invention relates to a novel therapeutic use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment of serious depression in humans, particularly for the treatment of a patients resistant to conventional anti-depressant treatments and for treatment of sleep/waking cycle disorders. | 2013-07-11 |
20130178494 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS - The present disclosure relates to new DNA-directed alkylating agents and water-soluble N-mustard agents with improved chemical stability and anti-tumor therapeutic efficacy. | 2013-07-11 |
20130178495 | IBUDILAST FOR RELIEVING NEGATIVE EFFECTS OF MEDICATION OVERUSE HEADACHE - Certain negative effects of medication overuse headache (MOH) are relieved by administering ibudilast or a pharmaceutically acceptable salt thereof. | 2013-07-11 |
20130178496 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2013-07-11 |
20130178497 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT - The present invention provides a heterocycle derivative having a superior amyloid β production inhibitory activity and/or a superior γ-secretase modulation activity, and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof. | 2013-07-11 |
20130178498 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 - The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators. | 2013-07-11 |
20130178499 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2013-07-11 |
20130178500 | HEXAHYDROPYRROLO[3,4-b]PYRROLE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF - Hexahydropyrrolo[3,4-b]pyrrole derivatives, preparation methods and pharmaceutical uses thereof are provided. Specifically, dipeptidyl peptidase IV inhibitors presented by following formula (I) are provided. Such compounds can be used for treating or preventing the diseases associated with dipeptidyl peptidase IV, such as diabetes, obesity and hyperlipemia. The compounds presented by formula (I) and pharmaceutically acceptable salts thereof, a method for preparing a pharmaceutical composition thereof and their uses in the manufacture of medicaments for treating or preventing the disease associated with dipeptidyl peptidase IV are provided. | 2013-07-11 |
20130178501 | MANUFACTURE OF LOZENGE PRODUCT WITH RADIOFREQUENCY - The present invention features a process for making a lozenge product including the steps of forming a powder blend containing an amorphous carbohydrate polymer into the desired shape of the lozenge product and applying radiofrequency energy to the shape for a sufficient period of time to soften or melt said amorphous carbohydrate polymer to fuse the shape into said lozenge product. | 2013-07-11 |
20130178502 | Pyridine Compounds for Controlling Invertebrate Pests I - The present invention relates to novel pyridine compounds of the formulae I and II, to their salts, to their tautomers, to their N-oxides, and to the salts of these N-oxides or tautomers. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests. The invention also relates to a method for controlling invertebrate pests by using these compounds. The invention further relates to plant propagation material and to agricultural compositions comprising said compounds. | 2013-07-11 |
20130178503 | METHODS OF TREATING HEMATOLOGIC MALIGNANCIES USING 6-CYCLOHEXYL-1-HYDROXY-4-METHYL-2(1H)-PYRIDONE - Provided herein are methods of treating a drug-resistant hematologic malignancy in a subject, which comprises administering to the subject a therapeutically effective amount of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, or a pharmaceutical salt or solvate thereof. | 2013-07-11 |
20130178504 | CRYSTALLINE FORMS OF FEBUXOSTAT - New forms of Febuxostat have been prepared and characterized. These forms are useful, for example, in the chronic management of hyperuricemia in patients with gout. | 2013-07-11 |
20130178505 | Compounds for the Inhibition of Cellular Proliferation - Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein. | 2013-07-11 |
20130178506 | ISOXAZOLE TREATMENTS FOR DIABETES - The present invention relates to compounds and methods for inducing synthesis and secretion of insulin from pancreatic beta cells. The methods may take place in vitro, ex vivo such as in isolates from adult mammalian tissue, or in vivo. Compounds and methods described herein may find use in the treatment of diabetes. | 2013-07-11 |
20130178507 | SUBSTITUTED BICYCLIC HCV INHIBITORS - Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C. | 2013-07-11 |
20130178508 | COSMETIC COMPOSITION - A highly moisturizing cosmetic composition having firmness/elasticity-improving effect, wrinkle-improving effect, and texture-improving effect can be provided by blending a metal phthalocyanine derivative or salt thereof in a cosmetic material. For the metal phthalocyanine derivative, iron phthalocyanine tetracarboxylic acid is particularly favorable. | 2013-07-11 |
20130178509 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 2013-07-11 |
20130178510 | CONNECTIVE TISSUE GROWTH FACTOR ANTISENSE OLIGONUCLEOTIDES - The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression. | 2013-07-11 |
20130178511 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA - The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles. | 2013-07-11 |
20130178512 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES - The present invention provides iRNA agents comprising at least one subunit of the formula (I): | 2013-07-11 |
20130178513 | MODULATION OF EIF4E EXPRESSION - Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided. | 2013-07-11 |
20130178514 | Use of miR-29 for Cell protection - The present invention relates to the regulation of apoptosis and expression of the BH3-only family of genes by miR-29. The invention further relates to the use of miR-29 to protect cells from apoptosis and to treat disorders associated with apoptosis. | 2013-07-11 |
20130178515 | PREDICTIVE MARKERS FOR TAXANE RESPONSIVENESS AND METHODS OF USE THEREOF - Taxanes are widely used in the treatment of breast cancer, although there are currently no validated predictive markers for taxane responsiveness. While the mechanism by which taxanes induce mitotic arrest is well documented, the signaling pathway that links mitotic arrest to cell death, is ill-defined. As described herein, the BH3-only protein Bad and Bik are prognostic indicators for overall survival after adjuvant taxane chemotherapy and a predictive marker for taxane responsiveness. | 2013-07-11 |
20130178516 | EXTRACTS OF CHENOPODIUM AMBROSIOIDES L., THE COMPOSITIONS COMPRISING SAID EXTRACTS, THE PREPARING PROCESS AND APPLICATION THEREOF - The present invention relates to plant extracts, specifically, the extracts of Chinese medicine | 2013-07-11 |
20130178517 | Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions - Disclosed are methods of treatment for adipogenic virus-related conditions. The methods may comprise administering a composition comprising an effective dose of an antiviral agent to a subject having an adipogenic adenovirus-related condition. Administration of the antiviral agent may prevent or reduce viral proliferation in the subject. The method may also include administering a composition comprising an effective dose of a therapeutic agent known to treat the adipogenic adenovirus-related condition in conjunction with the composition comprising an effective dose of an antiviral agent. Administration of the antiviral agent and the therapeutic agent may reduce or eliminate one or more symptoms of the adipogenic adenovirus-related condition more efficiently than administration of either the antiviral agent and the therapeutic agent alone. | 2013-07-11 |